



College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

**Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands**

DECENTRALISED PROCEDURE

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
MEDICINAL PRODUCT**

Metrobactin 250 mg tablets for dogs and cats

Date: 13 November 2015

MODULE 1

PRODUCT SUMMARY

Dutch Registration number	Reg NL 116425
EU Procedure number	NL/V/0193/001/DC
Name, strength and pharmaceutical form	Metrobactin 250 mg tablets for dogs and cats
Applicant	Le Vet Beheer Wilgenweg 7 3421 TV Oudewater The Netherlands
Active substance(s)	Metronidazole
ATC Vetcode	QP51AA01, QJ01XD01
Target species	dogs and cats
Indication for use	Treatment of gastrointestinal tract infections caused by <i>Giardia</i> spp.. Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteria (e.g. <i>Clostridia</i> spp.) susceptible to metronidazole.

Publicly available assessment report

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the website:

<http://mri.medagencies.org/veterinary/>

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of the original Decentralised procedure	23 September 2015
Concerned Member States for original procedure	AT, BE, BG, CY, CZ, DE, DK, EE, EL, ES, FI, FR, HR, HU, IE, IS, IT, LT, LU, LV, NO, PL, PT, RO, SE, SI, SK, UK

I. SCIENTIFIC OVERVIEW

Metrobactin 250 mg tablets for dogs and cats is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

Metrobactin 250 mg tablets for dogs and cats is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

The safety and efficacy aspects of Metrobactin 250 mg tablets for dogs and cats are based on bioequivalence with the Reference product Metrobac and the European reference product Metrobactin 250 mg tablets REG NL 108911.

Warnings statements and precautions are adopted from the reference product.

Additional statements have been added, based on increased knowledge and the current state of science. Adverse events, warnings and contraindications are indicated in the SPC.

II. QUALITY ASPECTS

A. QUALITATIVE AND QUANTITATIVE PARTICULARS

The tablets contain 250 mg Metronidazole and the following core excipients:

Chicken flavour, Dried yeast, Hydroxypropylcellulose, Microcrystalline cellulose, Sodium starch glycolate (type A) and Magnesium stearate.

The tablet is cross scored and meant to be broken in halves or quarters.

The tablets are packed in PVC/PE/PVDC-Al blisters, each containing 10 tablets.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

Publicly available assessment report

According to the current guideline the bioequivalence study can be waived because the Metronidazole tablets are identical (composition, quality of ingredients and manufacturing) to their reference products.

B. DESCRIPTION OF THE MANUFACTURING METHOD

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

The product is manufactured using conventional manufacturing techniques. However, suitable pre-approval validation results on two production scale batches of each tablet strength have been provided.

The tests performed during production are described.

C. CONTROL OF STARTING MATERIALS

The active substance Metronidazole is an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The CEP procedure has been employed.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Chicken flavour and Dried yeast comply to EC Flavouring Regulation 1334/2008. All other excipients are in conformity with the Ph.Eur. requirements.

None of the starting materials used are affected by the Note for Guidance on TSE/BSE.

D. CONTROL TESTS DURING THE MANUFACTURING PROCESS

Not applicable.

E. CONTROL TESTS ON THE FINISHED PRODUCT

The finished product specification controls the relevant parameters for the pharmaceutical form. All tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site has been provided demonstrating compliance with the specification.

F. STABILITY

The retest period of 48 months for metronidazole when stored under the approved conditions is evidenced by additional stability data.

Stability data on the finished product have been provided in accordance with applicable VICH guidelines. According to the stability results provided the claimed shelf life of 36 months can be granted for Metronidazole 250 mg mg tablets.

G. OTHER INFORMATION

None

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological, pharmacological and clinical tests are not required.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users / the environment / consumers. Additional statements have been added, based on increased knowledge and the current state of science. Adverse events, warnings and contraindications are indicated in the SPC.

III.A Safety Testing

User Safety

Being a generic procedure the applicant refers to the reference product for information on this section.

Additionally, the applicant has provided a user safety assessment in compliance with the relevant guideline. Combined with increased knowledge and the current state of science, warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Ecotoxicity

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required.

The environmental risk assessment can stop in Phase I because this product is intended for use in cats and dogs and a Phase II assessment is not deemed necessary.

The product is not expected to pose an unacceptable risk for the environment when used according to the SPC.

Publicly available assessment report

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

Tolerance in the Target Species of Animals

Additionally to the above, based on increased knowledge and the current state of science, warning statements and precautions have been added to the product literature ensuring safety to the target animals. Adverse events, warnings and contraindications are indicated in the SPC.

Resistance

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological and pharmacological and clinical tests are not required. However, the SPC and Product Literature are updated according to the Revised Guideline on the SPC for Antimicrobial Products (EMA/CVMP/SAGAM/383441/2005).

V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicines Agencies website (www.HMA.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Summary of change (Application number)	Section updated in Module 3	Approval date
Addition new CEP Holder (NL/V/0193/001-002/A/001)	N/A	18 March 2016
Change of the name of the veterinary medicinal product only in the CMS PL. (NL/V/0193/001-002/IB/002)	N/A	23 December 2016
Update of DDPS (NL/V/xxxx/WS/021; NL/V/0193/001-002/WS/003)	N/A	12 July 2019
Implementation of wording agreed by CA (NL/V/0193/001-002/IA/004)	N/A	7 February 2020
Minor change in the manufacturing process of the finished product (NL/V/0193/001-002/IA/005)	N/A	23 August 2020
Renewal (NL/V/0193/001-002/R/001)	N/A	21 November 2020
Addition of the manufacturer of the finished product (manufacturing process in whole, including primary and secondary packaging, batch testing and batch release) (NL/V/0193/001-002/IB/006/G).	N/A	9 July 2021